About ARE — Alexandria Real Estate Equities
Alexandria Real Estate Equities (NYSE: ARE) is the original life science REIT, founded in 1994 — it created the asset class. It owns and develops Class A laboratory campuses in the US's premier biotech clusters: Greater Boston, San Francisco Bay Area, San Diego, Seattle, and New York.
Analyst Ratings
| Average Price Target | $54.20 |
| High Price Target | $68.00 |
| Low Price Target | $42.00 |
| Upside from $45 | +20.4% |
Price Chart
Earnings & EPS History
Alpha One Investment Thesis
At $45, ARE trades at approximately 5.8× FFO — its cheapest multiple in a decade. The S&P 500-listed REIT has never been this cheap relative to its operational cash generation. The bear case rests almost entirely on a $1.7B Q4 2025 non-cash impairment, but the business underneath is resilient: 71% EBITDA margins, a 33% FFO payout ratio, and Q1 2026 results that beat consensus.
Life science lab space cannot be substituted — you cannot run a BSL-2 lab remotely. Alexandria's Mega Campus locations are irreplaceable, built over 30 years of embedded tenant relationships. With the analyst consensus target at $50–$58, the stock at $45 offers meaningful upside for patient capital.
- Trades at ~5.8× FFO — decade low, well below 18–22× historical average
- $1.7B impairment is non-cash and one-time; no impact on dividend coverage
- 6.4% yield with 33% FFO payout ratio — fortress dividend coverage
- Lab space is irreplaceable; no WFH headwind unlike conventional office
- Mega Campus moat with 30 years of embedded tenant relationships
- Q1 2026 beat consensus; full-year guidance reaffirmed by management
- Biotech funding headwinds could reduce leasing demand in 2026–27
- Rate environment puts continued pressure on REIT valuations broadly
- Occupancy softening — near-term lease expirations worth monitoring
- Revenue declined 3.4% in FY2025 — growth stall needs reversing
- $1.7B impairment signals some asset values have deteriorated
- Ongoing analyst price target cuts introduce near-term sentiment overhang
Signals
Joel S. Marcus, Executive Chairman, made multiple open-market purchases of ARE stock in early May 2026. On May 6 alone he acquired 7,500 shares across two transactions at weighted-average prices of $45.99 and $46.74. Across the May 4–6 window, Marcus made at least five separate purchases totalling approximately $668,000 — all at prices near the current entry level.
The chairman of a REIT buying half a million dollars of stock in the open market — not through options, not through compensation plans — is one of the cleanest signals available. He knows the assets better than anyone.
Thomas Gregory Calvin, EVP, purchased 1,000 shares on April 30, 2026. A secondary signal, consistent with the insider accumulation pattern across multiple levels of the executive team.
ARE's Board of Directors authorised a new $500 million common stock repurchase program running through December 31, 2026. This replaces the prior $500M program that expired at end of 2025. At current prices, a full deployment of this program would retire approximately 6.3% of shares outstanding — directly accretive to per-share metrics including FFO and dividend coverage.
In February 2026, Alexandria executed a major balance sheet move — buying back $1.33 billion in senior notes for approximately $952 million in cash, a discount of roughly 28% to face value. This reduces future interest obligations, shrinks the debt stack at below-par prices, and signals management confidence in the company's liquidity position. Net effect: stronger coverage ratios and a cleaner balance sheet heading into 2026.
Life Science Tenant Performance
ARE's rent is only as durable as its tenants' businesses. The charts below track the stock performance of ARE's primary customers — weighted by their share of ARE's revenue — over the past 8 months. Tenant health is a leading indicator for occupancy and rent renewal demand.
Financials
| EPS (FY2025 GAAP) | -$8.44 |
| FFO / Share | $7.70 |
| Adj. EBITDA Margin | 71% |
| Net Income (FY2025) | -$1.46B |
| Revenue (FY2025) | $2.99B |
| Rev Growth YoY | -3.4% |
| Return on Assets | — |
| Total Assets | $31.4B |
| Total Debt | $13.2B |
| Debt / EBITDA | 7.2× |
| Interest Coverage | 2.4× |
| Shares Outstanding | 176M |
| Book Value / Share | ~$56 |
| Beta | 0.78 |
Dividend
| Quarterly Dividend | $0.72 / share |
| Last Ex-Dividend | Mar 10, 2026 |
| Next Estimated Ex-Date | Jun 11, 2026 |
| Consecutive Dividend Years | 25+ |